Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Viewed this way, a definition is a decision mechanism. It distinguishes some elements of the universe from the others. Hence ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. /CNW/ — Equity Insider News Commentary – November’s wave of FDA oncology approvals signals the industry’s shift toward ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being ...

In anticipation of the coming Christmas holiday, Baylor’s advancement office is encouraging alumni with daily Advent ...